docetaxel
information and resources from the National Cancer Institute
NCI Thesaurus | docetaxel
A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent. NCI Thesaurus | docetaxel
A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Taxotere Aventis Pharmaceutical Nov 27 2002
Taxotere
Accel. Approv. (clinical benefit subsequently established) Treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy.
Aventis Pharmaceutical May 14 1996
Taxotere
For locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
Aventis Pharmaceutical Dec 23 1999
Taxotere
For the treatment of locally advanced or metastatic breast cancer which has progressed during anthracycline-based treatment or relapsed during anthracycline-based adjuvant therapy.
Aventis Pharmaceutical Jun 22 1998
Taxotere
in combination with cisplatin for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
Aventis Pharmaceutical Nov 27 2002
|
|
|
|
news articles
Taxotere (Docetaxel) Receives US FDA Approval For Use In Advanced ... Mar 23, 2006
DG News ...review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved Taxotere(R) (docetaxel) Injection Concentrate in ...
Taxotere Now Approved for Stomach Cancer Mar 31, 2006
ACS News Center, Drug maker sanofi-aventis says the US Food and Drug Administration has approved its drug docetaxel (sold as Taxotere) for people with advanced disease. ...
FDA Approvals: Aranesp, Taxotere, Leukine Mar 28, 2006
Medscape (subscription) ...an extended dosing regimen for darbepoetin alfa injection in the treatment of chemotherapy-induced anemia; a new indication for docetaxel injection, allowing ...
Not Achieving Undetectable PSA After Treatment Indicates Prostate ... Mar 26, 2006
eMaxHealth.com, ...treatment could be an indicator of prostate cancer-specific mortality and may require more aggressive treatment including chemotherapy, specifically Docetaxel. ...
Committee for Medicinal Products for Human Use Post-authorisation ... Mar 24, 2006
PharmaLive.com (press release), The new indication adopted by CHMP is: “Gastric Adenocarcinoma: Taxotere (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the ...
Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum ... Mar 30, 2006
PR Newswire (press release), ...a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel ...
Sanofi-Aventis: Taxotere fighting to maintain blockbuster status Mar 29, 2006
Pharmaceutical Business Review Taxotere (docetaxel), was approved by the US regulator in combination with cisplatin and 5-flurouracil (5-FU) as a first-line treatment for metastatic gastric ...
Threshold Announces Multiple Presentations on Oncology Pipeline at ... Mar 29, 2006
Yahoo! News (press release) ...planned presentations are as follows: Sunday, April 2, 2006 Abstract 515: Phase 1 trial of Glycolytic Inhibition with 2-Deoxyglucose and Docetaxel for Patients ...
Phase II Trial of Taxotere® and Xeloda® for Metastatic Gastric ... Mar 30, 2006
Cancer Consultants (press release), ...of Oncology, treatment of metastatic adenocarcinoma of the stomach or gastroesophageal junction with the chemotherapy drugs Taxotere® (docetaxel) and Xeloda ...
Taxotere® plus Gemzar® Provides AntiCancer Responses in ... Mar 29, 2006
Cancer Consultants (press release), ...to an article recently published in the International Journal of Cancer, the combination consisting of chemotherapy agents Taxotere® (docetaxel) and Gemzar ...
Positive Findings from Clinical Studies of Quadramet in Prostate ... Feb 27, 2006
DG News This phase 2 study was designed to evaluate the tolerability and efficacy of Quadramet in combination with docetaxel (Taxotere®), Aventis Pharmaceuticals, a ...
Vaccine and Antibody Treatment of Prostate Cancer Mar 22, 2006
Community Dispatch (press release) Patients who are chemotherapy naive either must have refused docetaxel based chemotherapy or not be a candidate for docetaxel based chemotherapy. ...
Positive Findings from Clinical Studies of QUADRAMET(R) in ... Feb 27, 2006
PR Newswire (press release), ...refractory prostate cancer." This phase II study was designed to evaluate the tolerability and efficacy of QUADRAMET in combination with docetaxel (Taxotere(R ...
Taxotere®/Platinol®/Herceptin® Effective in Locally Advanced ... Mar 22, 2006
Cancer Consultants (press release), ...to an early online article published in the Journal of Clinical Oncology, the treatment regimen consisting of Taxotere® (docetaxel), Platinol® (cisplatin ...
CMPH 20-23 March 2006 Initial Marketing Authorisation Applications ... Mar 25, 2006
Medical News Today (press release), Taxotere (docetaxel), from Aventis Pharma SA, to add the treatment of metastatic gastric adeno-carcinoma in combination with cisplatin and 5-fluorouracil. ...
Between 2010 and 2015 the Therapeutic Lung Cancer Drug Market is ... Mar 25, 2006
New Age Media Concepts (press release) Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventisi Taxotere (docetaxel), Bristol-Myers ...
FDA APPROVES TAXOTERE(R) FOR THE TREATMENT OF PATIENTS WITH ... Mar 24, 2006
PR Newswire (press release), THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED TAXOTERE(R) (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND 5-FLUOROURACIL FOR THE ...
UPDATE 2-Sanofi's Taxotere wins backing for approval Mar 24, 2006
Reuters Taxotere, known under its chemical name as docetaxel, is already used to treat breast cancer, non-small cell lung cancer and prostate cancer. ...
Taxotere OK'd for advanced stomach cancer Mar 23, 2006
United Press International The drug maker said the Food and Drug Administration OK'd Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and 5-fluorouracil ...
Point Therapeutics Reports Fourth Quarter and Year-End 2005 ... Mar 14, 2006
Genetic Engineering News, The first of two studies in this program was launched in October 2005; a 400 patient trial testing the combination of talabostat and docetaxel versus docetaxel ...
Taxotere Receives US FDA Approval For Use In Advanced Stomach ... Mar 24, 2006
Playfuls.com, ...review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved Taxotere (docetaxel) Injection Concentrate in ...
SD Pharmaceuticals Inc. Reports Positive Efficacy Data on Its Non ... Mar 24, 2006
Genetic Engineering News, ...shock, vein irritation and phlebitis associated with the currently marketed formulations; these include vinorelbine, docetaxel, paclitaxel, clarithromycin and ...
Oncologists Jumped Gun on Taxanes After Oral Presentation Mar 17, 2006
MedPage Today, The increase in the number of patients getting taxanes -- either Taxol or Taxotere (docetaxel) -- was steady at about 0.15% a month (with a 95% confidence ...
TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... Mar 23, 2006
Yahoo! News (press release) ...review of the supplemental new drug application (sNDA), the US Food and Drug Administration (FDA) has approved TAXOTERE® (docetaxel) Injection Concentrate in ...
MultiVu Video Feed: FDA Approves New Treatment For Patients With ... Mar 23, 2006
PR Newswire (press release), NEW YORK, March 23 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved TAXOTERE(R) (docetaxel) Injection Concentrate in combination with ...
Matrix Metalloproteinase Inhibitor Effective for Kaposi’s ... Mar 22, 2006
Cancer Consultants (press release), ...than doxorubicin. Both Taxotere® (docetaxel) and Taxol® have significant activity in recurrent Kaposi’s sarcoma. Matrix metalloproteinases ...
Taxotere Receives Positive Opinion from the Committee for ... Mar 24, 2006
PharmaLive.com (press release), Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval in Europe of TAXOTERE® (docetaxel) Injection Concentrate ...
Taxotere® Approved for Advanced Gastric Cancer Mar 24, 2006
Cancer Consultants (press release), The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Taxotere® (docetaxel) for the treatment of advanced gastric cancer. ...
FDA APPROVES NEW TREATMENT FOR PATIENTS WITH ADVANCED STOMACH ... Mar 23, 2006
PR Newswire (press release), The US Food and Drug Administration (FDA) has approved TAXOTERE® (docetaxel) Injection Concentrate in combination with cisplatin and 5-fluorouracil for the ...
GPC Biotech Presents New Satraplatin Clinical Data From ... Feb 27, 2006
Yahoo! News (press release) Seven patients in the study had hormone-refractory prostate cancer (HRPC), and all of the HRPC patients had received Taxotere® (docetaxel), with a median of ...
Spectrum presents new satraplatin prostate cancer data Feb 28, 2006
Pharmaceutical Business Review ...patients in the study had hormone-refractory prostate cancer (HRPC), and all of the HRPC patients had received Sanofi-Aventis' Taxotere (docetaxel), with a ...
Cell Genesys gives promising prostate cancer trial update Feb 28, 2006
Pharmaceutical Business Review ...median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Sanofi-Aventis' Taxotere (docetaxel) chemotherapy plus ...
Taxol® and Paraplatin® Superior to Novantrone® for Hormone ... Mar 10, 2006
Cancer Consultants (press release), Novantrone alone has been replaced by Taxotere® (docetaxel)-based regimens for the chemotherapy treatment of hormone refractory prostate cancer. ...
Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... Mar 6, 2006
Cancer Consultants (press release), Researchers affiliated with the FinHer Study have reported that Taxotere® (docetaxel) is superior to Navelbine® (vinorelbine) when given in addition to 5-FU ...
GPC Biotech Reports Financial Results for Fiscal Year 2005 Mar 14, 2006
PR Newswire (press release), Taxotere(R) (docetaxel) is a registered trademark of Aventis Pharma SA For further information, please contact: GPC Biotech AG Fraunhoferstr. ...
Treatment “Holidays� Effective in Hormone-Refractory Prostate ... Mar 1, 2006
Cancer Consultants (press release), ...a subgroup of 45 patients involved in a larger clinical trial referred to as the ASCENT trial in which treatment with Taxotere® (docetaxel) plus Calcitriol ...
Taxol® and Paraplatin® Superior to Novantrone® for Hormone ... Mar 10, 2006
Cancer Consultants (press release), More recently, however, Taxotere® (docetaxel)-based regimens have replaced Novantrone as initial chemotherapy regimens in the treatment of HRPC. ...
Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy ... Mar 13, 2006
PR Newswire (press release), ...published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel) chemotherapy plus ...
ASCO Prostate: Intermittent Chemotherapy Controls Androgen ... Feb 28, 2006
MedPage Today, The 56 patients were culled from 250 men who participated in the phase III randomized ASCENT trial, which compared Taxotere (docetaxel) plus a high-dose ...
GVAX® Vaccine Promising for Hormone-Refractory Prostate Cancer Feb 28, 2006
Cancer Consultants (press release), These results compare favorably to the median survival of less than 19 months for the treatment of HRPC with Taxotere® (docetaxel)/prednisone, which is the ...
GPC Biotech Submits CMC Section Of Satraplatin NDA 21 Dec 2005
BioWorld Online (subscription), ...patients, a Phase II combination trial with Taxol (paclitaxel) for inoperable lung cancer and a Phase I combination trial with Taxotere (docetaxel) that just ...
Little Difference between Docetaxel and Paclitaxel in Treating ... Dec 14, 2005
DG News ...is virtually no difference in disease-free survival when a regimen comprising doxorubicin and cyclophosphamide is followed by either docetaxel or paclitaxel. ...
Interim Analysis of Phase 3 Study Shows Taxotere (docetaxel)-Based ... Dec 16, 2005
DG News SAN ANTONIO, TX -- December 16, 2005 -- The Breast Cancer International Research Group (BCIRG) and the sanofi-aventis Group today announced the results from ...
(PRN) New Study Demonstrates Nonanthracycline Adjuvant Regimen TC ... Dec 11, 2005
Houston Chronicle, 11 /PRNewswire/ -- The final analysis of an AC/TC adjuvant chemotherapy trial showed that TC (Docetaxel/Cyclophosphamide, 4 cycles) produced a superior disease ...
Dose Dense Doxorubicin-Docetaxel Combination Comparable to ... Dec 13, 2005
DG News 2005 -- The pre-operative sequential combination of doxorubicin plus cyclophosphamide administered over four cycles followed by four cycles of docetaxel (AC-T ...
Neoadjuvant Docetaxel, Doxorubicin and Capecitabine Used in Women ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- The neoadjuvant combination of docetaxel (T), doxorubicin (A) and capecitabine (X) has demonstrated an encouraging ...
Paclitaxel, docetaxel show similar breast cancer benefit Dec 9, 2005
myDNA.com, Results from a clinical trial comparing the effectiveness of the drugs paclitaxel and docetaxel, delivered over two different dosing schedules, showed that ...
New Study Demonstrates Nonanthracycline Adjuvant Regimen TC ... Dec 12, 2005
PharmaLive.com (press release), HOUSTON, December 11, 2005 /PRNewswire/ -- The final analysis of an AC/TC adjuvant chemotherapy trial showed that TC (Docetaxel/Cyclophosphamide, 4 cycles ...
New Clinical Study of Phenoxodiol as Chemo-sensitizer for ... Nov 28, 2005
PR Newswire (press release), ...announced today plans for a Phase Ib/IIa clinical study of the investigational anti-cancer drug, phenoxodiol in combination with docetaxel for women with ...
Phenoxodiol - docetaxel combination for women with recurrent ... Dec 5, 2005
News-Medical.net, A clinical study of ovarian cancer initiated by investigators at Yale School of Medicine will combine the anti-cancer drug phenoxodiol with docetaxel for women ...
Short Course of Herceptin® in Patients with Breast Cancer Dec 9, 2005
Cancer Consultants (press release), In breast cancer patients treated with docetaxel or vinorelbine followed by FEC (5-fluorouracil, epirubicin, cyclophosphamide), a nine-week course of Herceptin ...
Two Types of Breast Cancer Treatments Show Similar Benefit Dec 9, 2005
PharmaLive.com (press release), WASHINGTON, December 8, 2005-Results from a clinical trial comparing the effectiveness of the drugs paclitaxel and docetaxel, delivered over two different ...
SD Pharma encouraged by pre-clinical studies on cancer treatment Dec 14, 2005
San Diego Daily Transcript (subscription), ...(News) reported Wednesday that it has completed a battery of pre-clinical studies on its novel formulation of Docetaxel or Taxotere. ...
First Line Treatment with Herceptin Improves Outcomes in Early ... Dec 9, 2005
DG News ..."At 23 month median follow-up, doxorubicin plus cyclophosphamide and docetaxel and trastuzumab and the regimen of trastuzumab, carboplatin and docetaxel ...
Non-Anthracycline Chemotherapy Regimen Plus Herceptin®: Effective ... Dec 13, 2005
Cancer Consultants (press release), A phase III randomized trial reported that the non-anthracycline containing chemotherapy regimen of Taxotere® (docetaxel) and Paraplatin® (carboplatin ...
Prostate Cancer: New choice for hormone refractory patients Dec 8, 2005
PharmaLive.com (press release), ...“Sanofi-Aventis’ Taxotere (docetaxel) has emerged as the only drug to demonstrate a survival advantage in hormone-refractory prostate cancer (HRPC). ...
Adjuvant Therapy with Taxotere® and Cytoxan® Improves Breast ... Dec 13, 2005
Cancer Consultants (press release), ...the standard chemotherapy combination of Adriamycin® (doxorubicin) and Cytoxan® (cyclophosphamide), adjuvant therapy with Taxotere® (docetaxel) and Cytoxan ...
NeuTec Pharma completes patient recruitment in breast cancer ... Dec 5, 2005
Biotech Intelligence (press release), ...pharmacokinetic, multi-centre, open label study is evaluating the safety and efficacy of Mycograb® administered in combination with Docetaxel in metastatic or ...
Taxane-Based Breast Cancer Treatment Cost-Effective Compared to 5 ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- Despite higher drug costs and more adverse effects, researchers say a combination of docetaxel, doxorubicin and ...
Treatment of Breast Cancer with Herceptin for Nine Weeks Dec 10, 2005
MedIndia, The women included in the study received docetaxel or vinorelbine and then FEC (5-fluorouracil, epirubicin, cyclophosphamide).Those whose HER-2 protein were ...
New Treatment For Pancreatic Cancer Allows Life-saving Surgery Dec 6, 2005
Science Daily (press release) In the Norris Cotton Cancer Center trial, 24 patients were treated with short course, high dose chemotherapy of docetaxel and gemcitabine, followed by a ...
Taxotere® Vs. Taxol® in Adjuvant Treatment of Breast Cancer Dec 14, 2005
Cancer Consultants (press release), Taxotere® (docetaxel) and Taxol® (paclitaxel) produce similar outcomes when given after Adriamycin® (doxorubicin) and Cytoxan® (cyclophosphamide) in the ...
Taxotere/Cyclophosphamide Offers Greater Disease-Free Survival for ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- The combination of docetaxel (Taxotere) and cyclophosphamide should replace doxorubicin (Adriamycin)/cyclophosphamide ...
Trastuzumab Used as First Line Therapy in Women Whose Cancer Has ... Dec 12, 2005
DG News ...the same time to progression and overall survival as what has been seen in other studies using trastuzumab in combination with either docetaxel or paclitaxel. ...
Taxotere® and Taxol® Produce Same Results Following AC in ... Dec 15, 2005
Cancer Consultants (press release), ...and Acute Leukemia Group G (CALGB) and the North Central Cancer Treatment Group (NCCTG) recently reported results that both Taxotere (docetaxel) and Taxol ...
Taxotere®/Cytoxan® Superior to Standard Adriamycin®/Cytoxan as ... Dec 14, 2005
Cancer Consultants (press release), Researchers from the US Oncology Research in Houston reported that the chemotherapy combination Taxotere (docetaxel) plus Cytoxan (cyclophosphamide) provides ...
Researchers study breast cancer therapy Dec 15, 2005
myDNA.com, It found that adjuvant chemotherapy with the drugs Taxotere (docetaxel) and Cytoxan (cyclophosphamide) improves disease-free survival rates by 33 percent over ...
Bioxel Pharma Announces Results for the Third Quarter of 2005 Nov 23, 2005
CCNMatthews (Communiqués de presse), ...generic market, we have significantly reduced our production costs and we have broadened our taxanes product line to paclitaxel and docetaxel manufactured by ...
American Pharmaceutical Partners to Merge with Parent Company ... Nov 28, 2005
PR Newswire (press release), Bound (nab(TM)) technology platform, with 6 INDs, including Coroxane(TM) for peripheral vascular disease in Phase II/III and nab(TM) docetaxel expected to ...
Early Use of Herceptin Cost-Effective if Survival Really Improves ... Dec 1, 2005
Cancerpage.com, The comparator was existing practice, in addition to a threshold analysis on the prices of Herceptin and Taxotere (docetaxel, Sanofi-Aventis) to target an ...
Cytokinetics Announces Clinical and Non-Clinical Results for ... Nov 17, 2005
PR Newswire (press release), ...from two Phase Ib combination trials, one evaluating ispinesib in combination with capecitabine and the other evaluating ispinesib in combination with docetaxel ...
Bioxel Pharma Broadens its Taxane Product Line Nov 18, 2005
CCNMatthews (press release), APIs) and developer of targeted oncology drugs, today announced the filing of a new patent covering the manufacturing of paclitaxel and docetaxel APIs by semi ...
Human Genome Sciences Reports Results of Phase 1 Clinical Trials ... Nov 17, 2005
PR Newswire (press release), ...results demonstrated that the in vitro cytotoxicity of HGS-ETR2 was amplified through the addition of chemotherapeutic agents including paclitaxel and docetaxel ...
Phenoxodiol Delays Tumor Progression in Late-Stage Hormone ... Nov 17, 2005
PR Newswire (press release), ...stage of development of phenoxodiol for prostate cancer would be to use it in patients who have failed to respond to both hormone therapy and docetaxel therapy ...
(PRN) Cytokinetics Announces Presentation of Ispinesib Data at San ... Dec 8, 2005
Houston Chronicle, ...cell lung, ovarian, and breast cancers and three Phase Ib clinical trials designed to evaluate ispinesib in combination with each of docetaxel, carboplatin and ...
American Pharmaceutical Partners to Merge with Parent Company ... Nov 28, 2005
PharmaLive.com (press release), We anticipate that at least 6 INDs will be filed through 2006 and 2007, including nab(TM)-docetaxel, a solvent-free nab(TM) form of the leading taxane Taxotere ...
Short-Course of Herceptin® Active with Taxotere® as Adjuvant ... Dec 9, 2005
Cancer Consultants (press release), Researchers from Finland reported that Taxotere (docetaxel) plus an anthracycline-based regimen in addition to a 9-week course of Herceptin appears promising ...
Sanofi-Aventis: Taxotere sales set for modest boost Dec 5, 2005
Pharmaceutical Business Review The FDA granted a six-month priority review to Sanofi-Aventis’s Taxotere (docetaxel) after clinical trial data showed significant increases in two-year ...
FDA Grants Priority Review to Taxotere for the Supplemental New ... Dec 2, 2005
PharmaLive.com (press release), Administration (FDA) has granted a six-month priority review for the supplemental new drug application (s-NDA) for Taxotere(R) (docetaxel) Injection Concentrate ...
Herceptin OK as upfront cancer drug Dec 9, 2005
Monsters and Critics.com, In Slamon`s study, patients were treated with three different regimens: One contained Adriamycin, cyclophosphamide and docetaxel (Taxotere); the same ...
Ritalin Conjugate Used to Treat "Chemo-Brain" in Breast Cancer ... Dec 13, 2005
DG News The most commonly used regimens were cyclophosphamide, doxorubicin, paclitaxel, 5-fluorouracil, methotrexate, docetaxel and carboplatin. ...
Non-Anthracycline Regimens Plus Herceptin Effective with Less ... Dec 9, 2005
Cancer Consultants (press release), III randomized trial (BCIRG 006 study) has indicated that the non-anthracycline containing chemotherapy regimen utilizing Taxotere® (docetaxel) and Paraplatin ...
(PRN) - Telik's TELINTRA Demonstrates Positive, Clinically ... Dec 11, 2005
Bolsamania.com, ...[+]. (PRN) - New Study Demonstrates Nonanthracycline Adjuvant Regimen TC (Docetaxel and Cyclophosphamide) Is Superior to Standard AC (Doxorubicin ...
SABCS: Taxotere-Cytoxan Combo Shows Survival Advantage in Breast ... Dec 12, 2005
MedPage Today, 12 - Adjuvant chemotherapy with Taxotere (docetaxel) and Cytoxan (cyclophosphamide) delivers 33% better disease-free survival than the standard regimen of ...
SABCS: No Differences Found In Taxane Treatment Results Dec 9, 2005
MedPage Today, Details of the 4,988-woman Eastern Cooperative Oncology Group E1199 study comparing Taxotere (docetaxel) and Taxol (paclitaxel) were released early at the San ...
Chemoradiation Shrinks Pancreatic Tumors to Operable Size Dec 8, 2005
MedPage Today, The trial tested a high-dose Taxotere (docetaxel) and Gemzar (gemcitabine) combination followed by twice-weekly Gemzar and external beam radiotherapy for six ...
Interim Analysis of Phase III Study Shows TAXOTERE(R)-Based ... Dec 8, 2005
PR Newswire (press release), Results from the BCIRG 006 study also show that a novel non-anthracycline-based regimen ("TCH") with TAXOTERE(R) (docetaxel), the platinum salt carboplatin and ...
ABI In $4B Merger With APP To Create Abraxis BioScience Nov 28, 2005
BioWorld Online (subscription), ABI's NAB-based pipeline also includes Coroxane, in Phase II/III trials for peripheral vascular disease, and NAB docetaxel, anticipated to enter the clinic in ...
Am Pharm Partners to merge with parent Nov 28, 2005
United Press International ...company will also have 6 investigational new drugs (INDs) in development,including Coroxane for peripheral vascular disease, and nab docetaxel, expected to ...
(PRN) - Engate Offers Reputation-Based Connection Management ... Nov 28, 2005
Bolsamania.com, ...(PRN) - New Clinical Study of Phenoxodiol as Chemo-sensitizer for Docetaxel in Ovarian Cancer Commences at Yale University School of Medicine ... [+. ...
I can't have drugs that will ease my agony ... they cost too much Dec 5, 2005
Glasgow Evening Times, The SMC said: "Docetaxel (the generic name for Taxotere) offers improvements in survival, pain control and quality of life compared with the standard ...
AEterna Zentaris appoints a Board Vice Chairman, a New Chair of ... Nov 21, 2005
Yahoo! News (press release) ...clinical drug development, he was involved in the early development of many of the agents now used routinely, including: Paclitaxel, Docetaxel, Gemcitabine, CPT ...
Gamma-linolenic acid inhibits action of Her-2/neu, responsible for ... Nov 20, 2005
Xagena.it, ...showed that supplementation with GLA sensitizes breast cancer cells to some chemotherapeutic drugs, such as Paclitaxel ( Taxol ), Docetaxel ( Taxotere ) and ...
|
|
